Mechanisms of Antibody-Mediated Toxin Neutralization

抗体介导的毒素中和机制

基本信息

  • 批准号:
    7174286
  • 负责人:
  • 金额:
    $ 43.69万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2004
  • 资助国家:
    美国
  • 起止时间:
    2004-02-01 至 2009-01-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Antibodies have been used to protect against the effects of biological toxins for over a century. It is generally accepted that the mechanism whereby antibodies protect is by blocking the entry of toxins into cells. However, this ignores an important body of evidence demonstrating that antibodies to the A-chain of A-B toxins have equal or greater neutralizing activity than anti-B chain antibodies. We will present data demonstrating this with ricin toxin. Based upon these results we have formed the hypothesis that antibodies can protect by altering the intracellular processing and routing of the toxin and that the affinity of antibody binding may determine its ability to do so. To test this hypothesis we propose the following Specific Aims: Specific Aim 1: To produce and characterize a panel of high affinity anti-ricin A chain antibodies. The relationship between antibody affinity, in vitro neutralization and in vivo protection will be studied. Specific Aim 2: To study the intracellular routing of fluorescent-labeled ricin toxin in the presence of neutralizing and non-neutralizing antibodies. Confocal, deconvolution, and electron microscopy, and subcellular isolations will be used to study effects of antibody on subcellular localization of ricin. Specific Aim 3: To study the intracellular association between toxin and antibody. Double-label studies and fluorescence-energy transfer (FRET) will be used to determine how long antibody remains bound to the toxin during intracellular processing. Ricin is a prototype A-B toxin, a group that includes many bacterial and plant toxins. In addition to defining basic processes, the studies proposed in this application have utility for the development of vaccines and treatments for intoxications.
描述(由申请方提供):抗体已被用于防止生物毒素的影响超过世纪。一般认为,抗体的保护机制是通过阻断毒素进入细胞。然而,这忽略了一个重要的证据主体,该证据表明针对A-B毒素的A链的抗体具有与抗B链抗体相等或更大的中和活性。我们将提供蓖麻毒素的数据来证明这一点。基于这些结果,我们已经形成了这样的假设,即抗体可以通过改变毒素的细胞内加工和路由来保护,并且抗体结合的亲和力可能决定其这样做的能力。为了验证这一假设,我们提出以下具体目标: 具体目标1:制备和表征一组高亲和力抗蓖麻毒素A链抗体。将研究抗体亲和力、体外中和和体内保护之间的关系。 具体目的2:研究荧光标记蓖麻毒素在中和和非中和抗体存在下的细胞内路径。共聚焦,去卷积,电子显微镜,和亚细胞分离将被用来研究抗体对蓖麻毒素的亚细胞定位的影响。 具体目的3:研究毒素与抗体的细胞内结合。将使用双标记研究和荧光能量转移(FRET)来确定抗体在细胞内处理期间保持与毒素结合多长时间。 蓖麻毒素是一种原型A-B毒素,包括许多细菌和植物毒素。除了定义基本过程之外,本申请中提出的研究还可用于开发中毒的疫苗和治疗。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Seth H. Pincus其他文献

Variable regions of antibodies to synthetic polypeptides--I. Characterization of an idiotope expressed on antibodies and T-cell factors.
合成多肽抗体的可变区--I.
  • DOI:
    10.1016/0161-5890(85)90130-0
  • 发表时间:
    1985
  • 期刊:
  • 影响因子:
    3.6
  • 作者:
    Seth H. Pincus;Shyr;M. Dorf;L. P. Ewing;Barbara A. Araneo
  • 通讯作者:
    Barbara A. Araneo

Seth H. Pincus的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Seth H. Pincus', 18)}}的其他基金

ANTI-HIV IMMUNOTOXINS
抗HIV免疫毒素
  • 批准号:
    7165110
  • 财政年份:
    2005
  • 资助金额:
    $ 43.69万
  • 项目类别:
Mechanisms of Antibody-Mediated Toxin Neutralization
抗体介导的毒素中和机制
  • 批准号:
    7015595
  • 财政年份:
    2004
  • 资助金额:
    $ 43.69万
  • 项目类别:
Mechanisms of Antibody-Mediated Toxin Neutralization
抗体介导的毒素中和机制
  • 批准号:
    6992213
  • 财政年份:
    2004
  • 资助金额:
    $ 43.69万
  • 项目类别:
Furin Inhibition in HIV Disease
HIV 疾病中的弗林蛋白酶抑制
  • 批准号:
    6954243
  • 财政年份:
    2004
  • 资助金额:
    $ 43.69万
  • 项目类别:
Furin Inhibition in HIV Disease
HIV 疾病中的弗林蛋白酶抑制
  • 批准号:
    6798030
  • 财政年份:
    2004
  • 资助金额:
    $ 43.69万
  • 项目类别:
Mechanisms of Antibody-Mediated Toxin Neutralization
抗体介导的毒素中和机制
  • 批准号:
    7346980
  • 财政年份:
    2004
  • 资助金额:
    $ 43.69万
  • 项目类别:
Mechanisms of Antibody-Mediated Toxin Neutralization
抗体介导的毒素中和机制
  • 批准号:
    7118820
  • 财政年份:
    2004
  • 资助金额:
    $ 43.69万
  • 项目类别:
Mechanisms of Antibody-Mediated Toxin Neutralization
抗体介导的毒素中和机制
  • 批准号:
    6846330
  • 财政年份:
    2004
  • 资助金额:
    $ 43.69万
  • 项目类别:
Furin Inhibition in HIV Disease
HIV 疾病中的弗林蛋白酶抑制
  • 批准号:
    6992176
  • 财政年份:
    2004
  • 资助金额:
    $ 43.69万
  • 项目类别:
ANTI-HIV IMMUNOTOXINS
抗HIV免疫毒素
  • 批准号:
    6970838
  • 财政年份:
    2004
  • 资助金额:
    $ 43.69万
  • 项目类别:

相似海外基金

University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
  • 批准号:
    10073243
  • 财政年份:
    2024
  • 资助金额:
    $ 43.69万
  • 项目类别:
    Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
  • 批准号:
    10752129
  • 财政年份:
    2024
  • 资助金额:
    $ 43.69万
  • 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
  • 批准号:
    2339201
  • 财政年份:
    2024
  • 资助金额:
    $ 43.69万
  • 项目类别:
    Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
  • 批准号:
    MR/Y008693/1
  • 财政年份:
    2024
  • 资助金额:
    $ 43.69万
  • 项目类别:
    Research Grant
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
  • 批准号:
    23K14783
  • 财政年份:
    2023
  • 资助金额:
    $ 43.69万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
  • 批准号:
    23KJ0394
  • 财政年份:
    2023
  • 资助金额:
    $ 43.69万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
  • 批准号:
    10076445
  • 财政年份:
    2023
  • 资助金额:
    $ 43.69万
  • 项目类别:
    Grant for R&D
PLA2G2D Antibodies for Cancer Immunotherapy
用于癌症免疫治疗的 PLA2G2D 抗体
  • 批准号:
    10699504
  • 财政年份:
    2023
  • 资助金额:
    $ 43.69万
  • 项目类别:
Genetic adjuvants to elicit neutralizing antibodies against HIV
基因佐剂可引发抗艾滋病毒中和抗体
  • 批准号:
    10491642
  • 财政年份:
    2023
  • 资助金额:
    $ 43.69万
  • 项目类别:
Novel Immunogens to Elicit Broadly Cross-reactive Antibodies That Target the Hemagglutinin Head Trimer Interface
新型免疫原可引发针对血凝素头三聚体界面的广泛交叉反应抗体
  • 批准号:
    10782567
  • 财政年份:
    2023
  • 资助金额:
    $ 43.69万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了